SEC Form 4 · accession 0001618835-18-000083
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Saundra L Pelletier
Officer — Chief Executive Officer · Director
Period of report
Aug 10, 2018
Accepted (ET)
Aug 13, 2018 · 6:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 10, 2018 | P | 10,000 | $2.11 | A | 341,813 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.11 to $2.12, inclusive. The reporting person undertakes to provide to Evofem Biosciences, Inc. (Evofem), any security holder of Evofem, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.